Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

A gut microbe makes a fatty acid that cuts artery plaque in half in mice (opens in a new tab)

medicalxpress.com · 2026-10-14

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of six claims match the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

  • 2 supported
  • 4 not covered
Open claim evidence
3
Source paper

Source layer

The 3 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredResearchers at institutions including Sun Yat-sen University and Shenzhen Bay Laboratory in China identified the substance as pentadecanoic acid, and the study was published in Nature.View evidenceHide evidence

Why this verdict

The paper profile supports the scientific point that pentadecanoic acid was identified as the principal bioactive substance. However, the supplied abstract-level profile does not provide author affiliations or journal-publication metadata, so the Sun Yat-sen University/Shenzhen Bay Laboratory and Nature-publication portions cannot be verified from the supplied evidence.

1

Study evidence

Bioactivity-guided screening revealed pentadecanoic acid (PA, C15:0) as a principal bioactive metabolite from Bacteroidota-derived material.

“Bioactivity-guided screening revealed pentadecanoic acid (PA, C15:0), a saturated odd-chain fatty acid, as a principal bioactive metabolite.”
Claim 2 of 6Not coveredIn mice prone to atherosclerosis, giving Bacteroides uniformis or pentadecanoic acid lowered LDL cholesterol and reduced plaque buildup, while heat-killed bacteria did not produce the same benefits.View evidenceHide evidence

As statedabout half

Why this verdict

The profile supports that live B. uniformis administration alleviated atherosclerosis in mice and that PA supplementation reduced plaque burden by about 50% and improved plasma lipid profiles, with LDL-clearance-related mechanism. But the abstract-level profile does not verify the heat-killed-bacteria comparison, does not give a quantified plaque effect for B. uniformis itself, and does not specifically state LDL-cholesterol lowering for every intervention in the way the story phrases it.

1

Study evidence

Administration of Bacteroides uniformis alleviates atherosclerosis in a mouse model and is associated with upregulation of hepatic LDL receptor expression and improved plasma lipid profiles.

“using a mouse model, we show that administration of Bacteroides uniformis alleviates atherosclerosis through the upregulation of hepatic low-density lipoprotein receptor expression.”
2

Study evidence

PA supplementation reduced atherosclerotic plaque burden by around 50% in mice.≈50% reduction

“PA supplementation reduced atherosclerotic plaque burden by around 50% and significantly improved plasma lipid profiles”
Claim 3 of 6Not coveredExperiments showed that pentadecanoic acid binds to and inhibits HMG-CoA reductase, increasing LDL receptor supply in liver cells; disabling LDL receptor production in the mouse liver eliminated the protection against plaque buildup.View evidenceHide evidence

Why this verdict

The profile supports the core mechanism that PA directly inhibits HMG-CoA reductase, suppresses hepatic cholesterol biosynthesis, promotes LDL-cholesterol removal, and is associated with increased hepatic LDLR expression. However, the supplied abstract-level evidence does not verify PA 'binding' details, the exact liver-cell context, or the specific loss-of-function experiment that disabling LDL receptor production in mouse liver eliminated plaque protection.

1

Study evidence

Administration of Bacteroides uniformis alleviates atherosclerosis in a mouse model and is associated with upregulation of hepatic LDL receptor expression and improved plasma lipid profiles.

“using a mouse model, we show that administration of Bacteroides uniformis alleviates atherosclerosis through the upregulation of hepatic low-density lipoprotein receptor expression.”
2

Study evidence

PA supplementation reduced atherosclerotic plaque burden by around 50% in mice.≈50% reduction

“PA supplementation reduced atherosclerotic plaque burden by around 50% and significantly improved plasma lipid profiles”
Claim 4 of 6Not coveredThe article says a small 2024 trial in women with fatty liver disease found that adding pentadecanoic acid to a Mediterranean-style dietary intervention further reduced LDL cholesterol, but a 2026 analysis of two long-running studies found no association between higher blood levels of the molecule and lower cardiovascular disease incidence.View evidenceHide evidence

Why this verdict

The supplied paper profile does not contain the cited small 2024 dietary trial or the claimed 2026 analysis of two long-running studies. The only human evidence in the profile is an abstract-level observational statement that PA was markedly depleted in patients with dyslipidaemia, without cohort or quantitative details. Therefore the story’s external-human-evidence claim cannot be verified against this abstract-level paper profile.

1

Study evidence

Pentadecanoic acid (PA, C15:0) is reported as markedly depleted in patients with dyslipidaemia compared with a reference group.

“PA is markedly depleted in patients with dyslipidaemia.”
Claim 5 of 6SupportedA common gut bacterium produces a molecule that slows cholesterol production in the liver, and when researchers gave that molecule to mice prone to artery disease, the animals developed roughly half as much fatty plaque as untreated controls.View evidenceHide evidence

As statedroughly half as much fatty plaque

Why this verdict

The abstract-level profile supports that bioactivity-guided screening identified pentadecanoic acid as a Bacteroidota/Bacteroides-derived bioactive metabolite, that PA suppresses hepatic cholesterol biosynthesis through HMG-CoA reductase inhibition, and that PA supplementation reduced atherosclerotic plaque burden by around 50% in mice. The headline-strength causal framing is limited to the mouse intervention and is therefore supported as stated for mice, though abstract-level details such as dose, sample size, and statistics are unavailable.

1

Study evidence

Bioactivity-guided screening revealed pentadecanoic acid (PA, C15:0) as a principal bioactive metabolite from Bacteroidota-derived material.

“Bioactivity-guided screening revealed pentadecanoic acid (PA, C15:0), a saturated odd-chain fatty acid, as a principal bioactive metabolite.”
2

Study evidence

PA supplementation reduced atherosclerotic plaque burden by around 50% in mice.≈50% reduction

“PA supplementation reduced atherosclerotic plaque burden by around 50% and significantly improved plasma lipid profiles”
Claim 6 of 6SupportedThe story emphasizes that the mouse findings do not establish a treatment for people and that larger human trials would be needed to determine whether pentadecanoic acid or gut microbes that make more of it can safely reduce heart attack- and stroke-causing artery disease.View evidenceHide evidence

Why this verdict

The profile’s main efficacy evidence is preclinical mouse work, and its human evidence is observational and abstract-level only. The story’s caution that the findings do not establish a human treatment and that larger human trials would be needed is consistent with the paper profile’s limitations and does not overstate the evidence.

1

Study evidence

Administration of Bacteroides uniformis alleviates atherosclerosis in a mouse model and is associated with upregulation of hepatic LDL receptor expression and improved plasma lipid profiles.

“using a mouse model, we show that administration of Bacteroides uniformis alleviates atherosclerosis through the upregulation of hepatic low-density lipoprotein receptor expression.”
2

Study evidence

PA supplementation reduced atherosclerotic plaque burden by around 50% in mice.≈50% reduction

“PA supplementation reduced atherosclerotic plaque burden by around 50% and significantly improved plasma lipid profiles”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • A 100-strain gut-bacterial survey found PA production across multiple Bacteroidota genera.

    The story focuses on B. uniformis as the bacterial source and does not reflect the broader strain-panel finding that PA production occurs across multiple Bacteroidota genera.

    From in vitro strain metabolite screen

  • The paper reports an observational human comparison in which PA was markedly depleted in patients with dyslipidaemia.

    The story mentions limited human evidence and external human studies, but it does not report the paper-profile human finding that PA was depleted in dyslipidaemia patients.

    From observational human cohort or case-control comparison

6 things the story did carry across
  • Bacteroides uniformis administration alleviated atherosclerosis in a mouse model and was linked to upregulated hepatic LDLR expression and improved lipid-profile readouts.
  • Bioactivity-guided screening identified pentadecanoic acid, PA/C15:0, as a principal bioactive metabolite.
  • PA supplementation in mice reduced atherosclerotic plaque burden by around 50% and significantly improved plasma lipid profiles.
  • Mechanistic evidence reported that PA directly inhibits HMG-CoA reductase, suppresses hepatic cholesterol biosynthesis, promotes plasma LDL-cholesterol removal, and increases hepatic LDLR expression.
  • The therapeutic/atheroprotective efficacy findings are from mouse models, so generalizability to humans is not established by the abstract-level evidence.
  • The human PA finding is observational and cannot establish causality.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalTest whether administration of Bacteroides uniformis causally alleviates atherosclerosis in a mouse model and define a liver LDLR-linked mechanism.in vivo animal intervention / microbial administrationExpand

In plain English

In a mouse atherosclerosis model, administration of the gut bacterium Bacteroides uniformis alleviates atherosclerosis and is reported to upregulate hepatic low‑density lipoprotein receptor (LDLR) expression, with associated improvements in atherosclerotic plaque burden and plasma lipid profiles (abstract-level report).

Key findings

  • Administration of Bacteroides uniformis alleviates atherosclerosis in a mouse model and is associated with upregulation of hepatic LDL receptor expression and improved plasma lipid profiles.
“using a mouse model, we show that administration of Bacteroides uniformis alleviates atherosclerosis through the upregulation of hepatic low-density lipoprotein receptor expression.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroIdentify the principal bioactive metabolite mediating the anti-atherosclerotic effect (bioactivity-guided screening implicating pentadecanoic acid, C15:0) and test its therapeutic effect in mice.bioactivity-guided fractionation and analytical identificationExpand

In plain English

From bioactivity-guided fractionation of Bacteroides/Bacteroidota-derived material, the study identifies pentadecanoic acid (PA, C15:0) as a principal bioactive metabolite and tests PA supplementation in a mouse atherosclerosis model, reporting ~50% reduction in plaque burden and improved plasma lipid profiles.

Key findings

  • Bioactivity-guided screening revealed pentadecanoic acid (PA, C15:0) as a principal bioactive metabolite from Bacteroidota-derived material.
  • PA supplementation in a mouse model reduced atherosclerotic plaque burden by ~50% and significantly improved plasma lipid profiles.~50% reduction in atherosclerotic plaque burden (as reported in abstract)
“Bioactivity-guided screening revealed pentadecanoic acid (PA, C15:0), a saturated odd-chain fatty acid, as a principal bioactive metabolite.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3in vivo animalIdentify the principal bioactive metabolite mediating the anti-atherosclerotic effect (bioactivity-guided screening implicating pentadecanoic acid, C15:0) and test its therapeutic effect in mice.in vivo supplementationExpand

In plain English

Bioactivity-guided screening identified pentadecanoic acid (PA, C15:0) as the principal microbially derived metabolite mediating anti-atherosclerotic effects; supplementation of purified PA in a mouse atherosclerosis model reduced atherosclerotic plaque burden by ~50% and improved plasma lipid profiles, with reported mechanistic evidence that PA directly inhibits HMG-CoA reductase, suppresses hepatic cholesterol biosynthesis, and promotes plasma LDL cholesterol removal.

Key findings

  • PA supplementation reduced atherosclerotic plaque burden by around 50% in mice.≈50% reduction
  • PA treatment significantly improved plasma lipid profiles.
“PA supplementation reduced atherosclerotic plaque burden by around 50% and significantly improved plasma lipid profiles”
What this piece can’t prove
  • Abstract does not report details on dosing regimen, treatment duration, mouse strain/sex/age, sample sizes, or statistical analyses for the PA supplementation experiments.
  • The abstract does not specify whether mechanistic assays demonstrating HMG-CoA reductase inhibition were performed in vitro, ex vivo, or in vivo, nor does it provide quantitative mechanistic effect sizes.
4in vitroEstablish a mechanism for PA action on cholesterol metabolism (direct inhibition of HMG-CoA reductase; reduced hepatic cholesterol biosynthesis; enhanced LDL-cholesterol clearance; increased hepatic LDLR expression).Expand

In plain English

Abstract reports that the microbial metabolite pentadecanoic acid (PA, C15:0) directly inhibits HMG-CoA reductase, suppresses hepatic cholesterol biosynthesis, increases hepatic LDL receptor (LDLR) expression, and promotes plasma LDL-cholesterol removal, providing a mechanistic basis for enhanced cholesterol clearance linked to atheroprotection.

Key findings

  • PA directly inhibits HMG-CoA reductase (reported in abstract).
  • PA suppresses hepatic cholesterol biosynthesis (reported in abstract).
“Mechanistically, PA enhances cholesterol clearance by directly inhibiting HMG-CoA reductase, suppressing hepatic cholesterol biosynthesis and promoting plasma low-density lipoprotein cholesterol removal.”
What this piece can’t prove
  • Summary is based solely on abstract statements; experimental details needed to evaluate validity (assay design, controls, replicates, concentrations, and statistical robustness) are not provided.
  • Abstract does not specify whether mechanistic evidence derives from purified enzyme assays, cultured cells, ex vivo tissue, or in vivo measurements, limiting interpretation of directness and physiological relevance.

1 further detail could not be confirmed from the summary.

5in vitroDetermine how broadly PA is produced across gut bacterial taxa using a strain panel screen.in vitro strain metabolite screenExpand

In plain English

The paper reports a cross-strain, in vitro survey of 100 gut bacterial strains and finds that production of the odd-chain fatty acid pentadecanoic acid (PA) is detected across multiple genera within the phylum Bacteroidota.

Key findings

  • PA production was detected across multiple genera of Bacteroidota in a screen of 100 gut bacterial strains.
“Analyses of 100 gut bacterial strains revealed that PA production occurs across multiple Bacteroidota genera.”
What this piece can’t prove
  • Unclear how representative the 100-strain panel is of overall gut microbial diversity or of Bacteroidota diversity in humans.

2 further details could not be confirmed from the summary.

6human in vivoAssess whether PA is altered in human dyslipidaemia/atherosclerosis-relevant states (reported depletion in patients with dyslipidaemia).observational human cohort or case-control comparisonExpand

In plain English

The abstract reports that pentadecanoic acid (PA, C15:0) is markedly depleted in patients with dyslipidaemia based on a human observational comparison; the abstract does not provide quantitative effect sizes, cohort details, biospecimen or assay information, or adjustment/ statistical details for this comparison.

Key findings

  • Pentadecanoic acid (PA, C15:0) is reported as markedly depleted in patients with dyslipidaemia compared with a reference group.
“PA is markedly depleted in patients with dyslipidaemia.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 40 candidate papers

Candidate

Author response for "Influence of different pore-forming agents on the properties of CuSn10 alloy prepared by powder metallurgy"

2026 · Crossref

Source (opens in a new tab)

And 34 more candidates considered.